BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eribulin mesylate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eribulin mesylate\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07255612-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07255612)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Bone Marro
 w Protection\, Safety\, Efficacy of Trilaciclib and Eribulin in Locally Ad
 vanced or Metastatic TNBC(Triple-negative Breast Cancer)\nEstimated primar
 y completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07255612
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006273-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Eribulin mesylate: Phase 1 readout est. (NCT06006273)
DESCRIPTION:Eribulin mesylate\, phase 1.\nStudy: A Phase Ib Trial of Eribul
 in in Combination With Irinotecan and Temozolamide in Children With Relaps
 ed or Refractory Solid Tumors\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylat
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 006273
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328738-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Eribulin mesylate: Phase 1 readout est. (NCT06328738)
DESCRIPTION:Eribulin mesylate\, phase 1\, Breast Cancer.\nStudy: ELVN-002 W
 ith Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors\, Colorectal and Br
 east Cancer\nEstimated primary completion: January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06328738
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04078295-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT04078295)
DESCRIPTION:Eribulin mesylate\, phase 1/2.\nStudy: A Study of E7389 Liposom
 al Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04078295
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731153-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT06731153)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: JAK1 Inhib
 itor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06731153
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458674-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT05458674)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Tucatinib+
 Trastuzumab+Eribulin in HER2+ MBC\nEstimated primary completion: 1 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 58674
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Ad
 vanced or Metastatic HER2-Negative Breast Cancer\nEstimated primary comple
 tion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06942234
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03237780-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT03237780)
DESCRIPTION:Eribulin mesylate\, phase 2.\nStudy: Atezolizumab With or Witho
 ut Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced 
 or Metastatic Urothelial Cancer\nEstimated primary completion: 30 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0323
 7780
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07333937)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: Neratinib 
 Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanc
 ed Breast Cancer\nEstimated primary completion: 20 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007559-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: ASPEN-09-0
 3: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy 
 in Metastatic HER2-Positive Breast Cancer\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eribuli
 n-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07007559
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, Breast Cancer.\nStudy: Phase Ib
 /II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive 
 Advanced Breast Cancer\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205185-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07205185)
DESCRIPTION:Eribulin mesylate\, phase 2.\nStudy: A Multicenter\, Single-arm
 \, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eri
 bulin\, Anlotinib\, and Radiotherapy for the Treatment of Patients With Ad
 vanced Soft Tissue Sarcoma.\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720
 5185
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202316-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT03202316)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Atezolizumab\, Cobimetinib\, and Eribulin in Treating Patients 
 With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03202316
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441512-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07441512)
DESCRIPTION:Eribulin mesylate\, phase 2\, Breast Cancer.\nStudy: A Phase II
 \, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in C
 ombination With Eribulin in Pretreated Advanced Triple-negative Breast Can
 cer Harboring a PIK3CA Mutation\nEstimated primary completion: 15 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 41512
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Eribulin mesylate: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Eribulin mesylate\, phase 3\, Breast Cancer.\nStudy: A Study Co
 mparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Each in Co
 mbination With Physician's Choice Chemotherapy\, for the Treatment of Part
 icipants With Metastatic HER2-positive Breast Cancer\nEstimated primary co
 mpletion: 28 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04986
 579
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530057-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT05530057)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Eribulin With or Without Trastuzumab-biosimilar in Patients Wit
 h HER2-overexpressed Recurrent or Stage IV Breast Cancer\nEstimated primar
 y completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05530057
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449222-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT06449222)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Safety and Preliminary Effectiveness of BNT327\, an Investigati
 onal Therapy for Breast Cancer\, When Given in Combination With Chemothera
 py\nEstimated primary completion: August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06449222
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889688-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Eribulin mesylate: Phase 3 readout est. (NCT06889688)
DESCRIPTION:Eribulin mesylate\, phase 3\, Breast Cancer.\nStudy: Phase III 
 Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherap
 y in Advanced Triple-Negative Breast Cancer\nEstimated primary completion:
  31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/er
 ibulin-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06889688
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520760-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Eribulin mesylate: Phase 2 readout est. (NCT07520760)
DESCRIPTION:Eribulin mesylate\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Multicenter\, Single-Arm\, Phase II Exploratory Study of Erib
 ulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic 
 Breast Cancer Previously Treated With Antibody-Drug Conjugates\nEstimated 
 primary completion: 30 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07520760
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811232-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT07811232)
DESCRIPTION:Eribulin mesylate\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of AL58805 in Advanced\, Metastatic GYN\, STS or Brea
 st Cancers\nEstimated primary completion: 1 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07811232
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957431-7635@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Eribulin mesylate: Phase 1 readout est. (NCT06957431)
DESCRIPTION:Eribulin mesylate\, phase 1.\nStudy: Zanzalintinib Combined Wit
 h Eribulin in Advanced Liposarcoma and Leiomyosarcoma\nEstimated primary c
 ompletion: 31 May 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06957431
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
